Theravance Biopharma (TBPH) SVP Aine Miller Buys 18,750 Shares

Aine Miller, the Senior Vice President of Development and Head of the Ireland Office at TBPH, purchased 18,750 shares of the company on June 19, 2026. This insider purchase was executed at a transaction value of $0, indicating a non-cash transaction, which can sometimes be part of a compensation package or stock option exercise.

Insider Buying and Selling at Theravance Biopharma, Inc.

Aine Miller's recent purchase adds to the insider activity at TBPH. On June 15, Rhonda Farnum, the Senior Vice President of Communications and Medical Affairs, sold 13,314 shares at an average price of $16.39 per share under a planned sale. Earlier, on June 12, insiders including Donal O'Connor, Dean Mitchell, and Susannah Gray each bought 13,398 shares, also at a transaction value of $0, reflecting similar non-cash transactions.

Other Institutional Activity in TBPH

Several institutional investors have also been active in TBPH. Newtyn Management, LLC increased its holdings by 541,629 shares, resulting in a 12.6% increase, ending with 4,841,629 shares valued at approximately $78.58 million. BlackRock, Inc. added 245,765 shares, marking a 6.1% increase, bringing its total to 4,296,290 shares worth about $69.73 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 1,783,753 shares valued at $28.95 million.

Theravance Biopharma, Inc. Stock Down 0.3%

Shares of TBPH traded near $16.97 on Wednesday. The company's stock has attracted attention due to insider activity and institutional interest. While specific market metrics like market cap and P/E ratio are not available, the stock's price movement indicates active trading and potential investor interest.

Analysts Set New Price Targets

Several analysts have weighed in on TBPH. On April 7, 2026, B. Riley Securities maintained its hold rating with a $17 price target. Earlier, on March 23, TD Cowen also maintained a hold rating with a $15 target. HC Wainwright & Co. continues to rate the stock as a buy, with a target of $15 set on March 4, 2026. Overall, the consensus among analysts shows mixed ratings with varying price targets, reflecting different outlooks on the company's prospects.

Bottom Line

Aine Miller's purchase of 18,750 shares of TBPH underscores a level of confidence in the company's future. The activity reflects broader insider and institutional interest in the stock. Investors often track such moves as potential indicators of a company's prospects, although it's important to remember that these transactions reflect past actions and may not represent current positions.